September 2, 2026- The early adoption phase of artificial intelligence (AI) has largely passed. Medical groups that once debated whether to invest in AI are now managing multiple tools that touch scheduling, clinical documentation, point-of-care decisions and revenue cycle, according to Premier.
It’s easy for the excitement of efficiency gains and data-driven decisions to perpetuate a cycle of launch, measure and repeat. But even as setting baselines and measuring the impact of individual AI tools becomes standard practice, many medical groups are missing an equally important step: evaluating those tools as a portfolio. Health systems that measure AI’s impact tool-by-tool may systematically understate its value, miss the returns that build between tools, and may risk letting one tool’s failure overshadow the successes of others.
Continue Reading from Premier Inc.